Carvedilol improves uptake-1 in patients with systolic congestive heart failure

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 2, 2012, Pages 175-181

  MacHida, Maiko ^a   Takechi, Shigeru ^b   Fujimoto, Tetsuya ^a   Kakinoki, Shigeo ^c   Nomura, Akikazu ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b Department of Cardiovascular Medicine   (Japan)

^c Otaru Kyokai Hospital   (Japan)

Author keywords

3,4 dihydroxyphenyl glycol; carvedilol; congestive heart failure; norepinephrine; sympathetic nervous system

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NITRATE; NORADRENALIN; VERAPAMIL;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; REST; STANDING; SYSTOLIC HEART FAILURE; TREADMILL EXERCISE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CARBAZOLES; EXERCISE TEST; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROPANOLAMINES; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84857060992     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823a94a2     Document Type: Article

References (30)

1. Keating GM, Jarvis B, Carvedilol. A review of its use in chronic heart failure. Drugs. 2003;63:1697-1741. (Pubitemid 36999963)
2. Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation. 2000;102:484-486. (Pubitemid 30639961)
3. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-2199. (Pubitemid 35222212)
4. Hori M, Sasayama S, Kitabatake A, et al. MUCHA Investigators. Lowdose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004;147:324-330. (Pubitemid 38176834)
5. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996; 94:2817-2825. (Pubitemid 26411746)
6. Esler M, Kaye D, Lambert G, et al. Adrenergic nervous system in heart failure. Am J Cardiol. 1997;80:7L-14L. (Pubitemid 27528443)
7. Esler M, Kaye D. Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev. 2000; 5:17-25. (Pubitemid 30301508)
8. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56:331-349. (Pubitemid 39096594)
9. Goldstein DS, Eisenhofer G, Stull R, et al. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-220. (Pubitemid 18092256)
10. Eisenhofer G, Esler MD, Meredith IT, et al. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation. 1992;85:1775-1785.
11. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676. (Pubitemid 26131343)
12. Meredith IT, Eisenhofer G, Lambert GW, et al. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation. 1993;88:136-145. (Pubitemid 23195442)
13. Machida M, Sakaguchi A, Kamada S, et al. Simultaneous analysis of human plasma catecholamines by high-performance liquid chromatography with a reversed-phase triacontylsilyl silica column. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:249-254. (Pubitemid 43075459)
14. Machida M, Watanabe M, Takechi S, et al. Measurement of carvedilol in plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;798: 187-191. (Pubitemid 37487717)
15. Packer M, Lukas MA, Tenero DM, et al. 369 Study Group. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol. 2006;98:39L-45L.
16. Fletcher GF, Froelicher VF, Hartley LH, et al. Exercise standards: a statement for health professionals from the American Heart Association. Circulation. 1990;82:2286-2322.
17. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823. (Pubitemid 14035089)
18. Bristow M. Antiadrenergic therapy of chronic heart failure. Circulation. 2003;107:1100-1102.
19. Takechi S, Nomura A, Shimono H, et al. Recovery of cardiac norepinephrine concentration and tyrosine hydroxylase activity by the central alpha2-adrenoceptor agonist guanabenz in rats with aortic constriction. J Cardiovasc Pharmacol. 1999;33:409-413. (Pubitemid 29101984)
20. Fujimura M, Yasumura Y, Ishida Y, et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail. 2000;6:3-10. (Pubitemid 30161411)
21. Chizzola PR, Gonçalves de Freitas HF, Marinho NV, et al. The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure. Int J Cardiol. 2006;106:29-34. (Pubitemid 41728906)
22. Kurose M, Okumura K, Ogawa H, et al. Reduced cardiac extraction of norepinephrine and epinephrine in patients with heart failure: correlation with left ventricular function. Int J Cardiol. 1994;47:21-29. (Pubitemid 24347746)
23. Münch G, Rosport K, Bültmann A, et al. Cardiac overexpression of the norepinephrine transporter ruptake-1 results in marked improvement of heart failure. Circ Res. 2005;97:928-936. (Pubitemid 41552679)
24. Xing J, Koba S, Kehoe V, et al. Interstitial norepinephrine concentrations in skeletal muscle of ischemic heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H1190-H1195. (Pubitemid 47254221)
25. Kieback AG, Rödiger O, Jaenecke H, et al. Hemodynamic effects of alpha1-adrenoceptor antagonist, doxazosin, in patients with chronic congestive heart failure. J Cardiovasc Pharmacol. 2005; 46:399-404. (Pubitemid 41407565)
26. Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic betaadrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
27. Schweizer W. Beta-blockers present status and future prospects. In: Brunner H, ed. The Antihypertensive Effect of Beta-Blockers. Bern, Germany: Hans Huber Publishers; 1974:19-33.
28. Yamada Y, Ito K, Nakamura K, et al. Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structurepharmacokinetic/ pharmacodynamic relationship. Biol Pharm Bull. 1993; 16:1251-1259. (Pubitemid 24049991)
29. Akers WS, Cassis LA. Presynaptic modulation of evoked NE release contributes to sympathetic activation after pressure overload. Am J Physiol Heart Circ Physiol. 2004;286:H2151-H2158. (Pubitemid 38685229)
30. Maebara C, Ohtani H, Sugahara H, et al. Nightmares and panic disorder associated with carvedilol overdose. Ann Pharmacother. 2002;36: 1736-1740. (Pubitemid 35265612)